There seems to be a misunderstanding as the term “retatrutide” is not found in the provided sources. However, the sources do provide information on liraglutide, a glucagon-like peptide-1 analogue used for weight management. Clinical trials, such as the 56-week randomized controlled trial, provide evidence for the efficacy and safety of liraglutide 3.0 mg in weight management for overweight or obese adults, showing significant weight loss and generally mild to moderate gastrointestinal adverse events [4].
What the AI assistants say
The AI assistants collectively discuss retatrutide, an investigational triple hormone receptor agonist that targets GIP, GLP-1, and glucagon receptors. They agree that retatrutide has shown significant weight loss effects in clinical trials, with the most substantial evidence coming from a Phase 2 trial and early Phase 3 results. The AI assistants also concur that retatrutide’s mechanism of action involves synergistic effects on insulin secretion, gastric emptying, energy expenditure, and appetite suppression. However, they differ in the details of the clinical trials and the specific outcomes reported. While one AI assistant provides a detailed breakdown of the mechanisms and clinical trial data, another focuses more on the overall potential of retatrutide in weight management.
What the research actually shows
Based on the provided research corpus, the discussion on retatrutide is not applicable as the compound is not mentioned. Instead, the research provides evidence for liraglutide, a glucagon-like peptide-1 analogue used for weight management. A key clinical trial mentioned in the sources is a 56-week, randomized, placebo-controlled trial that evaluated the efficacy and safety of liraglutide 3.0 mg for weight management in overweight or obese adults [4]. This trial, conducted across 191 sites in 27 countries, enrolled patients with a BMI of 30 or more (obese) or a BMI of 27 or more (overweight) with at least one weight-related health condition [4]. The results showed that a significantly higher percentage of participants in the liraglutide group achieved at least 5% weight loss compared to the placebo group (63.2% vs. 23.6%, p<0.001) [4]. The liraglutide group also experienced a significantly greater mean weight loss compared to the placebo group (−6.8 kg vs. −2.8 kg, p<0.001) [4]. In terms of safety, the most common adverse events in the liraglutide group were gastrointestinal, including nausea, diarrhea, and constipation, which were generally mild to moderate in severity [4]. There were no significant differences in serious adverse events or severe hypoglycemia between the liraglutide and placebo groups [4].
Where the AI consensus and the research diverge
The AI assistants’ consensus on retatrutide does not align with the research corpus, as the provided sources discuss liraglutide instead. The research corpus provides evidence for the efficacy and safety of liraglutide 3.0 mg in weight management, showing significant weight loss and generally mild to moderate gastrointestinal adverse events [4].
Bottom line: The research corpus provides evidence for the efficacy and safety of liraglutide 3.0 mg in weight management for overweight or obese adults, demonstrating significant weight loss and generally mild to moderate gastrointestinal adverse events [4].
References
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- Aging Prevention for All
- Contemporary Endocrinology_ Leptin
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss_ Systematic Review and Meta-Analyses of Randomised C
- Energy Metabolism and Obesity_ Research and Clinical Applications
- GHRH, GH, and IGF-1_ Basic and Clinical Advances
- Gene Therapy_ Therapeutic Mechanisms and Strategies
- Gene and Cell Therapy_ Therapeutic Mechanisms and Strategies
- Growth Hormone Secretagogues in Clinical Practice
- Hypothalamic Integration of Energy Metabolism
- Living a Fully Optimized Life
- Peptide Protocols Volume One — William A Seeds MD
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptides_ Chemistry and Biology, 2nd Edition
- Pharmacotherapy of obesity_ clinical trials to clinical practice
- Weight Management_ State of the Science and Opportunities for Military Programs
Continue your research
Part of our Retatrutide: Research Evidence & Trials guide.
- What preclinical studies have been conducted to explore the potential benefits of retatrutide?
- What Phase III clinical trials have been conducted to evaluate the efficacy of retatrutide for weight loss?
- What real-world evidence is available regarding the effectiveness of retatrutide in weight loss management?
Related topics:
- How does retatrutide compare to other weight loss medications in terms of efficacy and side effects?
- What are the long-term health benefits of using retatrutide for weight management?
- What are the most common adverse events reported in clinical trials involving retatrutide?